Lineage Cell Therapeutics (LCTX) Net Margin (2010 - 2026)

Lineage Cell Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 278.96% for Q1 2026.

• In Q1 2026, Net Margin rose 17444.0% year-over-year to 278.96%; the TTM figure through Mar 2026 stood at 358.96% (down 16189.0% YoY), while the FY2025 annual figure was 435.33%, down 23971.0% from the prior year.
• Net Margin for Q1 2026 stood at 278.96%, down from 103.77% in the prior quarter.
• The five-year high for Net Margin was 79.41% in Q3 2024, with the low at 815.01% in Q2 2025.
• The 5-year median for Net Margin is 225.77% (2023), against an average of 304.9%.
• The sharpest annual moves came in 2022 and 2025: Net Margin surged 82077 bps in 2022, then tumbled 43260 bps in 2025.
• Lineage Cell Therapeutics' Net Margin stood at 330.08% in 2022, then jumped by 32 bps to 225.77% in 2023, then surged by 50 bps to 113.32% in 2024, then increased by 8 bps to 103.77% in 2025, then plunged by 169 bps to 278.96% in 2026.
• Business Quant data shows LCTX's Net Margin at 278.96% in Q1 2026, 103.77% in Q4 2025, and 512.01% in Q3 2025.